S1C4:Drug Product Submissions: eCTD Module 3

原文始发于微信公众号(化学音乐文化):S1C4:Drug Product Submissions: eCTD Module 3

S1C4:Drug Product Submissions: eCTD Module 3

JanFourman,PhD, EdD,MBA, MSRA

S1C4:Drug Product Submissions: eCTD Module 3

Eli Lilly – Pharma registration for diabetes/endocrine, women/men’s health, neural science, oncology, bone/muscle/joint therapeutic areas – 5 years
Eli Lilly – Pharmacovigilance – 7 years
Eli Lilly – Regulatory Intelligence – 3 Years
Purdue University and Roche Diagnostics – Teaching global pharma development, Africa and US
Consultant for Indiana Technical Assistance Program
Invited conference speaker
Published author

S1C4:Drug Product Submissions: eCTD Module 3
S1C4:Drug Product Submissions: eCTD Module 3

扫描左侧二维码,获取视频课;扫描右侧二维码,获取音频课

Drug Product Submissions: eCTD Module 3

S1C4:Drug Product Submissions: eCTD Module 3

Quality Data of Module 3:

Chemistry, Manufacturing and Controls (CMC)

Drug Substance and Product

Formulation

Packaging

Distribution

Packaging Agenda

Defines package “labeling” and its purpose

Briefly reviews the label development processFrom Target Product Profile (TPP) to Printed Packaging Development (PPD)

PPD logistics

PPD challenges

Submission amendments

Misbranding

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2020年2月18日 00:00
下一篇 2020年2月18日 12:25

相关推荐

公众号
公众号
分享本页
返回顶部
FDA批准首款NASH/MASH新药,中国药企如何分享这个百亿美元大蛋糕?点击观看直播